Accelerated approvals for cancer drugs is a good idea in theory. This US Food and Drug Administration (FDA) pathway allows promising new cancer agents to reach the market, and patients, sooner. But speed can come at a price. The bargain the FDA has struck with manufacturers is companies can use less robust metrics — surrogate …
